Overview of Treatment Plan Quality in a High Dose Rate Prostate Brachytherapy Workflow

Overview

Journal Brachytherapy

Specialty Radiology

Date 2024 Sep 29

PMID 39343653

Authors

J V Panetta

I Veltchev

E Horwitz

M Hallman

K Wong

R A Price

C M C Ma

Affiliations

Soon will be listed here.

Abstract

Purpose: High dose rate brachytherapy (HDR-BT) has been shown to be an effective treatment for prostate cancer, with treatment plan quality dependent on a number of factors. In this work, we report on the overall performance of our ultrasound (US)-based workflow and the impact of several treatment-specific variables.

Methods And Materials: Patients who underwent HDR-BT (boost, monotherapy, and retreatment) using Varian Bravos/US from 2021 to 2023 were sampled for this study. Treatment plan quality was analyzed and plans were categorized with regard to a number of metrics, including: prostate volume, treating physician, planning physicist, number of needles included, estimated planning time, rectum-prostate separation, and bladder-prostate separation. The performance of this program was compared to the performance of our program using previously used modality combinations: Varian Varisource/US, Elekta microSelectron/CT.

Results: Plan quality for our Bravos/US workflow was shown to be consistently above acceptability criteria for all personnel involved; on average: prostate V100%: 98.9% ± 0.1%, rectum V75%: 0.04 ± 0.01 cc, bladder V75%: 0.06 ± 0.01cc, urethra V125%: 0.00 ± 0.00 cc. Prostate coverage was statistically improved with this workflow compared to that using our previous modalities. There was a statistical correlation between organ-at-risk sparing/prostate coverage ratio and prostate volume, number of needles/prostate volume, bladder-prostate separation, and rectum-prostate separation. There was no correlation between plan quality and planning time.

Conclusions: Our US-based HDR-BT program led to target coverage and organ-at-risk sparing that exceeded department thresholds. Results were acceptable regardless of the personnel involved and improved plan quality was obtained using more needles/prostate volume and increased spacing between the prostate and the rectum and bladder.

References

Lee C, Koleoso O, Deng M, Veltchev I, Lin T, Hallman M . A dosimetric analysis of rectal hydrogel spacer use in patients with recurrent prostate cancer undergoing salvage high-dose-rate brachytherapy. Brachytherapy. 2023; 22(5):586-592. PMC: 10527788. DOI: 10.1016/j.brachy.2023.06.003. View

Kennedy A, Douglass M, Santos A . Being certain about uncertainties: a robust evaluation method for high-dose-rate prostate brachytherapy treatment plans including the combination of uncertainties. Phys Eng Sci Med. 2023; 46(3):1115-1130. PMC: 10480262. DOI: 10.1007/s13246-023-01279-8. View

Podgorsak A, Venkatesulu B, Abuhamad M, Harkenrider M, Solanki A, Roeske J . Dosimetric and workflow impact of synthetic-MRI use in prostate high-dose-rate brachytherapy. Brachytherapy. 2023; 22(5):686-696. DOI: 10.1016/j.brachy.2023.05.005. View

Even A, Nuver T, Westendorp H, Hoekstra C, Slump C, Minken A . High-dose-rate prostate brachytherapy based on registered transrectal ultrasound and in-room cone-beam CT images. Brachytherapy. 2013; 13(2):128-36. DOI: 10.1016/j.brachy.2013.08.001. View

Jayakody M, Jeyasugiththan J, Rajasooriyar C, Chougule A . Dosimetry procedure to verify dose in High Dose Rate (HDR) brachytherapy treatment of cancer patients: A systematic review. Phys Med. 2022; 96:70-80. DOI: 10.1016/j.ejmp.2022.02.022. View

Parzen J, Ye H, Gustafson G, Yan D, Martinez A, Chen P . Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer. Radiother Oncol. 2020; 147:123-129. DOI: 10.1016/j.radonc.2020.03.033. View

Batchelar D, Chung H, Loblaw A, Law N, Cisecki T, Morton G . Intraoperative ultrasound-based planning can effectively replace postoperative CT-based planning for high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2016; 15(4):399-405. DOI: 10.1016/j.brachy.2016.04.003. View

Dahn H, Oliver P, Allen S, Cherpak A, Syme A, Patil N . Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study. Adv Radiat Oncol. 2019; 4(4):641-648. PMC: 6817543. DOI: 10.1016/j.adro.2019.05.005. View

Demanes D, Ghilezan M . High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy. 2014; 13(6):529-41. DOI: 10.1016/j.brachy.2014.03.002. View

10.

Banerjee S, Kataria T, Gupta D, Goyal S, Bisht S, Basu T . Use of ultrasound in image-guided high-dose-rate brachytherapy: enumerations and arguments. J Contemp Brachytherapy. 2017; 9(2):146-150. PMC: 5437087. DOI: 10.5114/jcb.2017.67456. View

11.

Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D . Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2010; 82(1):204-12. DOI: 10.1016/j.ijrobp.2010.10.009. View

12.

Lee P, Ruth K, Lee D, Hallman M, Chen D, Wong J . Comparison of perioperative and subacute postoperative complications between LDR and HDR monotherapy brachytherapy for prostate cancer. Brachytherapy. 2024; 23(5):559-568. PMC: 11426183. DOI: 10.1016/j.brachy.2024.06.001. View

13.

Zhang H, Kang S, Ali N, Baran A, Bylund K, Gentile D . Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results. Adv Radiat Oncol. 2020; 5(3):388-395. PMC: 7276678. DOI: 10.1016/j.adro.2020.02.002. View

14.

Solanki A, Mysz M, Patel R, Surucu M, Kang H, Plypoo A . Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions. Adv Radiat Oncol. 2019; 4(1):103-111. PMC: 6349651. DOI: 10.1016/j.adro.2018.10.004. View

15.

White E, Kamrava M, DeMarco J, Park S, Wang P, Kayode O . High-dose-rate prostate brachytherapy consistently results in high quality dosimetry. Int J Radiat Oncol Biol Phys. 2012; 85(2):543-8. DOI: 10.1016/j.ijrobp.2012.03.035. View

16.

Smith W, Lewis C, Bauman G, Rodrigues G, DSouza D, Ash R . Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. Int J Radiat Oncol Biol Phys. 2007; 67(4):1238-47. DOI: 10.1016/j.ijrobp.2006.11.027. View

17.

Bolling T, Moustakis C, Elsayed H, Muller S, Weining C, Reinartz G . Rectum dose reduction and individual treatment plan optimization for high-dose-rate prostate brachytherapy. Brachytherapy. 2007; 6(4):280-5. DOI: 10.1016/j.brachy.2007.06.001. View

18.

Chicas-Sett R, Celada-Alvarez F, Roldan S, Rodriguez-Villalba S, Santos-Olias M, Soler-Catalan P . Interobserver variability in rectum contouring in high-dose-rate brachytherapy for prostate cancer: A multi-institutional prospective analysis. Brachytherapy. 2017; 17(1):208-213. DOI: 10.1016/j.brachy.2017.09.015. View

19.

Poder J, Koprivec D, Dookie Y, Howie A, Cutajar D, Damato A . HDR prostate brachytherapy plan robustness and its effect on in-vivo source tracking error thresholds: A multi-institutional study. Med Phys. 2022; 49(6):3529-3537. PMC: 9322430. DOI: 10.1002/mp.15658. View

20.

Potharaju M, Subramanaiam R, Venkataraman M, Perumal K, Ramakrishnan B, Vangara R . A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer. Cureus. 2015; 7(8):e303. PMC: 4570880. DOI: 10.7759/cureus.303. View